Bibliography
- Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998;80:10-23
- Vlodavsky I, Abboud-Jarrous G, Elkin M, et al. The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 2006;35:116-27
- Vlodavsky I, Ilan N, Nadir Y, et al. Heparanase, heparin and the coagulation system in cancer progression. Thromb Res 2007;120(Suppl 2):S112-20
- Vreys V, David G. Mammalian heparanase: what is the message? J Cell Mol Med 2007;11:427-52
- Amirkhosravi A, Meyer T, Amaya M, et al. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 2007;33:643-52
- Shworak NW. Heparan sulfate proteoglycans. In: Aird WC, editor, Endothelial biomedicine. Cambridge: Cambridge University Press; 2007. p. 947-59
- Iozzo MV. Proteoglycans: structure, biology and molecular interactions. New York: Marcel Dekker, Inc.; 2000. p. 27-59
- Linhardt RJ, Dordick JS, Deangelis PL, Liu J. Enzymatic synthesis of glycosaminoglycan heparin. Semin Thromb Hemost 2007;33:453-65
- Proteoglycans and glycosaminoglycans, maintained by Bob Lauder. Available from: http://biol.lancs.ac.uk/gig/pages/toppage.htm [Last accessed 25 January 2008]
- Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007;446:1030-7
- Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Ann Rev Biochem 2002;71:435-71
- Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest 2001;108:169-73
- Fico A, Maina F, Dono R. Fine-tuning of cell signalling by glypicans. Cell Mol Life Sci 2007 [Epub ahead of print]
- Mousa SA. Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovasc Drug Rev 2004;22:121-34
- Mousa SA. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Semin Thromb Hemost 2007;33:524-33
- Guerrini M, Guglieri S, Naggi A, et al. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost 2007;33:478-87
- Gallagher JT. Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 2001;108:357-61
- Backen AC, Cole CL, Lau SC, et al. Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer 2007;96:1544-8
- Chen JL, Hong J, Lu JL, et al. Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma. World J Gastroenterol 2007;13:457-61
- Bar-Ner M, Eldor A, Wasserman L, et al. Inhibition of heparanase-mediated degradation of extra cellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 1987;70:551-7
- Hostettler N, Naggi A, Torri G, et al. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J 2007;21:3562-72
- Borsig L. Non-anticoagulant effects of heparin in carcinoma metastasis and Trousseau's syndrome. Pathophysiol Haemost Thromb 2003;33(Suppl 1):64-6
- Mousa SA, Linhardt R, Francis JL, Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost 2006;96:816-21
- Ono K, Ishihara M, Ishikawa K, et al. Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung. Br J Cancer 2002;86:1803-12
- Stevenson JL, Varki A, Borsig L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res 2007;120(Suppl 2):S107-11
- Yoshitomi Y, Nakanishi H, Kusano Y, et al. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett 2004;207:165-74
- Gao Y, Li N, Fei R, et al. P-Selectin-mediated acute inflammation can be blocked by chemically modified heparin, RO-heparin. Mol Cells 2005;19:350-5
- Kouretas PC, Hannan RL, Kapur NK, et al. Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: role of inhibitory guanine nucleotide proteins. J Mol Cell Cardiol 1998;30:2669-82
- Ferro V, Dredge K, Liu L, et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 2007;33:557-68
- Fairweather JK, Hammond E, Johnstone KD, Ferro V. Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88. Bioorg Med Chem 2008;16(2):699-709
- Weitz JI, Linkins LA. Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opin Investig Drugs 2007;16:271-82
- Karoli T, Liu L, Fairweather JK, et al. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J Med Chem 2005;48:8229-36
- Ludwig RJ, Alban S, Bistrian R, et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 2006;95:535-40
- Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005;11(19 Pt 1):7003-11
- Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003;23:2110-5
- Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 2007:CD006652
- Zacharski LR. Anticoagulants in cancer treatment: Malignancy as a solid phase coagulopathy. Cancer Lett 2002;186:1-9
- Zacharski LR. Malignancy as a solid phase coagulopathy: implications for the etiology, pathogenesis and treatment of cancer. Semin Thromb Hemost 2003;29:239-46
- Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007;95:507-12
- von Delius S, Ayvaz M, Wagenpfeil S, et al. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost 2007;98:434-9
- Nakchbandi W, Müller H, Singer MV, et al. Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma. Scand J Gastroenterol 2006;41:1095-104
- Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9
- von Tempelhoff GF, Harenberg J, Niemann F, et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000;16:815-24
- Haas SK, Kakkar AK, Kemkes-Matthes B, et al. Prevention of VTE with LMWH in patients with metastatic breast or lung cancer-results of the TOPIC studies [abstract OR059]. J Thromb Haemost 2005;3(Suppl 1)
- Henry BL, Monien BH, Bock PE, Desai UR. A novel allosteric pathway of thrombin inhibition: exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids. J Biol Chem 2007;282:31891-9
- Lv H, Yu G, Sun L, et al. Elevated level of glycosaminoglycans and altered sulfation pattern of chondroitin sulfate are associated with differentiation status and histological type of human primary hepatic carcinoma. Oncology 2008;72:347-56
- Theocharis AD, Tsara ME, Papageorgacopoulou N, et al. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta 2000;1502:201-6
- Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA. Distribution and changes of glycosaminoglycans in neoplasias of rectum. Anticancer Res 1995;15:2107-12
- Kennett EC, Davies MJ. Degradation of matrix glycosaminoglycans by peroxynitrite/peroxynitrous acid: evidence for a hydroxyl-radical-like mechanism. Free Radic Biol Med 2007;42:1278-89
- Kramer A, van den Hoven M, Rops A, et al. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol 2006;17:2513-20
- Ames BN. Endogenous oxidative DNA damage, aging, and cancer. Free Radic Res Commun 1989;7:128-38
- Cerutti PA. Oxy-radicals and cancer. Lancet 1994;344:862-3
- Grant D, Long WF, Mackintosh G, Williamson FB. The antioxidant activity of heparins. Biochem Soc Trans 1996;24:194S
- Vismara E, Pierini M, Guglieri S, et al. Structural modification induced in heparin by a Fenton-type depolymerization process. Semin Thromb Hemost 2007;33:466-77
- Metcalfe DD, Thompson HL, Klebanoff SJ, Henderson WR Jr. Oxidative degradation of rat mast-cell heparin proteoglycan. Biochem J 1990;272:51-7
- Zielonka J, Rybak M, Celińska J, et al. Effect of heparin on viologen-stimulated enzymatic NADH depletion. Chem Res Toxicol 2006;19:668-73
- Baldus S, Rudolph V, Roiss M, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006;113:1871-8
- Ross MA, Long WF, Williamson FB. Inhibition by heparin of Fe(II)-catalysed free-radical peroxidation of linolenic acid. Biochem J 1992;286:717-20
- Ross MA, Long WF, Williamson FB. Heparin reduces Fe(II)-catalyzed peroxidation of linolenic acid. Biochem Soc Trans 1992;20:6S
- Albertini R, Rindi S, Passi A, et al. The effect of heparin on Cu(2+)-mediated oxidation of human low-density lipoproteins. FEBS Lett 1995;377:240-2
- Albertini R, Rindi S, Passi A, et al. Heparin protection against Fe2+ -and Cu2+ -mediated oxidation of liposomes. FEBS Lett 1996;383:155-8
- Rajeswari A, Varalakshmi P. Low molecular weight heparin protection against oxalate-induced oxidative renal insult. Clin Chim Acta 2006;370:108-14
- Manduteanu I, Dragomir E, Voinea M, et al. Enoxaparin reduces H2O2-induced activation of human endothelial cells by a mechanism involving cell adhesion molecules and nuclear transcription factors. Pharmacology 2007;79:154-62
- Poyrazoglu OK, Dogukan A, Yalniz M, et al. Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients. Ren Fail 2006;28:723-7
- Aoyagi K, Kuzure Y, Shahrzad S, et al. Inhibition by heparin of protein kinase C activation and hydroxyl radical generation in puromycin aminonucleoside treated isolated rat hepatocytes. Mol Cell Biochem 2003;244:3-9
- Levenson CW, Tassabehji NM. Iron and ageing: an introduction to iron regulatory mechanisms. Ageing Res Rev 2004;3:251-63
- Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005;202:199-211
- Kehrer JP. The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 2000;149:43-50
- Spiteller G. Lipid peroxidation in aging and age-dependent diseases. Exp Gerontol 2001;36:1425-57
- Cook CI, Yu BP. Iron accumulation in aging: modulation by dietary restriction. Mech Ageing Dev 1998;102:1-13
- Zacharski LR, Chow BK, Howes PS, et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease. JAMA 2007;297:603-10
- Zacharski LR, Chow BK. Iron reduction and cardiovascular outcomes [Letter-to-editor]. JAMA 2007;297:2075-6
- Zacharski LR, Chow BK, Howes PS, et al. Reducing iron stores lowers cancer risk in patients with peripheral arterial disease [abstract 2665]. ASH Annual Meeting Abstracts; 2007;110(11)
- Lapenna D, Mezzetti A, de Gioia S, et al. Heparin: does it act as an antioxidant in vivo? Biochem Pharmacol 1992;44:188-91
- Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160(2):181-8
- Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin [letter]. Lancet 1992;339(8807):1476
- Hettiarachchi RJ, Smorenburg SM, Ginsberg J, et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82(2):947-52
- Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22(10):1944-8
- Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23(10):2130-5
- Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2(8):1266-71
- Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006;81(6):758-67
- Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23(10):2123-9
- Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007;110(5):1149-61
- Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007;5(4):729-37